Anaptysbio (ANAB) Accounts Payables (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Accounts Payables data on file, last reported at $7.5 million in Q1 2026.

• Quarterly Accounts Payables rose 22.77% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.5 million (up 22.77% YoY) and the FY2025 annual result came in at $3.9 million, down 3.27% from the prior year.
• Accounts Payables improved to $7.5 million in Q1 2026, from $3.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $7.5 million in Q1 2026 to a low of $1.6 million in Q2 2022.
• A 5-year average of $4.1 million and a median of $3.9 million in 2025 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables tumbled 61.32% — and 2023, when it surged 200.0%.
• Tracing ANAB's Accounts Payables over 5 years: stood at $2.8 million in 2022, then jumped by 68.75% to $4.7 million in 2023, then dropped by 14.81% to $4.0 million in 2024, then retreated by 3.27% to $3.9 million in 2025, then surged by 94.19% to $7.5 million in 2026.
• The last three Accounts Payables figures came in at $7.5 million (Q1 2026), $3.9 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.